In a patient with severe pulmonary arterial hypertension (WHO class III/IV), non‑vasoreactive, already on amlodipine and losartan, how should I initiate ambrisentan 10 mg daily and tadalafil 40 mg daily?

Initiating Ambrisentan 10 mg + Tadalafil 40 mg Daily in Severe Non-Vasoreactive PAH

Critical First Step: Discontinue Amlodipine and Losartan

You must stop amlodipine and losartan immediately before starting PAH-specific therapy. 1 These medications are not recommended in PAH unless required for specific comorbidities (hypertension, coronary disease, left heart failure), and in severe WHO class III/IV PAH they provide no benefit and may cause harm through systemic hypotension without improving pulmonary hemodynamics. 1

---

Confirm You Are NOT a Vasoreactive Patient

Do not use calcium-channel blockers in this patient. 2 Only ~10% of idiopathic PAH patients demonstrate acute vasoreactivity, and CCBs without documented positive vasoreactivity testing can cause life-threatening hypotension and right-ventricular ischemia. 2 Since this patient is already on amlodipine without benefit and has severe disease (WHO class III/IV), they are definitively non-vasoreactive. 1

---

High-Risk Assessment Requires Intravenous Prostacyclin First

For WHO functional class IV patients, intravenous epoprostenol must be initiated before or simultaneously with oral combination therapy. 2, 3 Epoprostenol is the only PAH-specific treatment proven to reduce mortality in high-risk patients. 2, 3

High-risk features that mandate IV prostacyclin include: 1

• WHO functional class IV
• Rapid disease progression
• Clinical evidence of right ventricular failure
• 6-minute walk distance <200 meters
• Right atrial pressure >20 mmHg
• Cardiac index <2.0 L/min/m²
• Pericardial effusion on echocardiography

If this patient is WHO class III (not IV) without these high-risk features, you may proceed directly to oral combination therapy. 1, 2

---

Initiating Ambrisentan + Tadalafil Combination

Starting Doses and Titration

Start both drugs simultaneously at lower doses and titrate to target over 2–4 weeks: 1

• Ambrisentan: Begin 5 mg once daily, increase to 10 mg once daily after 2 weeks if tolerated
• Tadalafil: Begin 20 mg once daily, increase to 40 mg once daily after 2 weeks if tolerated

The target doses are ambrisentan 10 mg daily and tadalafil 40 mg daily. 1, 2 This upfront combination has been shown to delay clinical failure and improve 6-minute walk distance compared to monotherapy. 1, 4

Monitoring During Titration

• Check blood pressure before each dose increase—hold or reduce dose if systolic BP <95 mmHg 1
• Monitor for headache (most common side effect, often improves with time) 4
• Check liver function tests at baseline, then monthly for first 3 months (ambrisentan can cause transaminitis, though less than bosentan) 1, 4
• Check hemoglobin at baseline and every 1–3 months (ERAs can cause anemia) 1
• Confirm negative pregnancy test before starting and monthly thereafter (both drugs are teratogenic) 1, 4

---

Essential Supportive Care to Initiate Simultaneously

Diuretics for Right Ventricular Failure

Start or optimize loop diuretics immediately for fluid retention and right heart failure. 2, 3 This is a Class I recommendation and critical in severe PAH. 2

Supplemental Oxygen

Prescribe continuous oxygen therapy if arterial oxygen tension is consistently <60 mmHg (8 kPa) or to maintain saturations >90%. 2, 3 This is mandatory in severe PAH. 2

Anticoagulation Consideration

Consider warfarin (target INR 1.5–2.5) in idiopathic or heritable PAH. 2 However, in connective tissue disease-associated PAH, weigh thrombotic risk against bleeding risk (e.g., thrombocytopenia). 5

Vaccinations

Administer influenza and pneumococcal vaccines. 1, 2, 3

Contraception Counseling

Pregnancy is absolutely contraindicated—maternal mortality is 30–50%. 1, 2, 3 Ensure reliable contraception (barrier methods preferred; avoid estrogen-containing contraceptives). 1

---

Reassessment at 3–4 Months

Perform comprehensive re-evaluation including right heart catheterization at 3–4 months. 1, 2

Target Low-Risk Profile: 2

• WHO functional class I–II
• 6-minute walk distance >440 meters
• BNP/NT-proBNP <50 ng/L or normal
• No pericardial effusion
• Right atrial pressure <8 mmHg
• Cardiac index >2.5 L/min/m²

If the patient remains intermediate- or high-risk (approximately 50% of patients), escalate to triple therapy by adding a prostacyclin pathway agent. 1, 2, 6 Options include inhaled treprostinil, subcutaneous treprostinil, or intravenous epoprostenol. 1

---

Common Pitfalls to Avoid

• Do not start both drugs at full dose immediately—titrate to minimize hypotension and headache 1
• Do not combine riociguat with tadalafil—this combination is contraindicated due to safety concerns 2
• Do not delay referral to a specialized PH center—these patients require expert multidisciplinary care 1, 2, 3
• Do not continue amlodipine/losartan "just in case"—they provide no PAH benefit and complicate hemodynamic management 1
• Do not skip the 3–4 month catheterization—clinical assessment alone misses hemodynamic non-responders who need escalation 1, 2

---

Ongoing Monitoring Every 3–6 Months

• WHO functional class 2, 3
• 6-minute walk distance 2, 3
• BNP/NT-proBNP 2, 3
• Echocardiography (RV size/function, pericardial effusion) 2, 3
• Liver function tests and hemoglobin 1, 4

The goal is achieving and maintaining low-risk status; failure to do so mandates therapeutic escalation. 5, 2